By Fineline Cube 
Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that it has completed an equity investment in Suisselle SA, a Swiss‑based medical‑aesthetic company, and has signed a formal investment and subscription agreement. The deal will deepen the strategic partnership and position both companies to jointly capture the growing global medical‑aesthetic market.
Investment Highlights
| Item | Detail |
|---|---|
| Investor | Sihuan Pharma (HKG: 0460) |
| Target | Suisselle SA (Switzerland) |
| Deal Structure | Equity investment + subscription agreement |
| Key Asset | CELLBOOSTER skin‑booster product line |
| Post‑Deal Rights | Permanent exclusive distribution of CELLBOOSTER in China for Sihuan Pharma |
| Strategic Rationale | Leverage Suisselle’s European platform to accelerate sales of Sihuan‑owned “Meiyan Space” products abroad |
Strategic Impact
- Strengthened Supply Chain – Sihuan Pharma will now own permanent exclusive distribution rights for CELLBOOSTER, solidifying its position as the sole Chinese distributor following its 2022 partnership.
- Global Market Expansion – By tapping Suisselle’s established European platform, the companies will jointly promote Meiyan Space‑developed products in Europe and other overseas markets.
- Product Portfolio Diversification – The Group will continue to import and launch innovative aesthetic products from Suisselle and other European partners, enriching China’s domestic aesthetic matrix.
Future Collaboration
- Joint R&D & Marketing – Sihuan Pharma will be deeply involved in the operation and development of CELLBOOSTER, driving localized innovation and marketing campaigns.
- Platform Synergy – Suisselle’s existing distribution network in Europe will serve as a launchpad for Sihuan‑owned products, while Sihuan’s market expertise will help Suisselle penetrate the Chinese market.
- Long‑Term Growth – The partnership aims to become a leading “global‑to‑local” model in the medical aesthetic industry, combining Swiss technology with Chinese market execution.
About Sihuan Pharma
Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) is a China‑based biopharmaceutical company focusing on the discovery, development, and commercialization of innovative medical‑aesthetic and therapeutic products.
About Suisselle
Suisselle SA is a Swiss medical‑aesthetic company specializing in advanced skin‑boosting technologies, including the CELLBOOSTER® platform.-Fineline Info & Tech